Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2014First federal award
$16.1MFederal grants as PI25 awards
0Patents grantedNone matched
197Papers5,779 citations
Federal awards and patents by year
AwardsPatents
25 awards · $16.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 23, 2024 | NIH | STTR Phase II Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | $999K | Chicago Biosolutions, Inc. |
| Apr 27, 2023 | NIH | STTR Phase II Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | $999K | Chicago Biosolutions, Inc. |
| May 5, 2022 | NIH | STTR Phase II Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | $2.0M | Chicago Biosolutions, Inc. with UNIVERSITY OF ILLINOIS AT CHICAGO |
| Feb 14, 2022 | NIH | STTR Phase I Furopyrimidines as novel inhibitors of henipaviruses | $300K | Chicago Biosolutions, Inc. |
| Jul 14, 2021 | NIH | STTR Phase II 4-(Aminomethyl) benzamides as novel anti-Ebola agents | $982K | Chicago Biosolutions, Inc. |
| Apr 1, 2021 | NIH | STTR Phase II Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | $300K | Chicago Biosolutions, Inc. |
| Jan 11, 2021 | NIH | STTR Phase I Furopyrimidines as novel inhibitors of henipaviruses | $599K | Chicago Biosolutions, Inc. with UNIVERSITY OF ILLINOIS AT CHICAGO |
| Jul 1, 2020 | NIH | STTR Phase II 4-(Aminomethyl) benzamides as novel anti-Ebola agents | $962K | Chicago Biosolutions, Inc. |
| Mar 13, 2020 | NIH | STTR Phase I Development of group 2 influenza A virus entry inhibitors | $300K | Chicago Biosolutions, Inc. |
| Aug 16, 2019 | NIH | STTR Phase II 4-(Aminomethyl) benzamides as novel anti-Ebola agents | $2.9M | Chicago Biosolutions, Inc. with UNIVERSITY OF ILLINOIS AT CHICAGO |
| Apr 1, 2019 | NIH | STTR Phase I Development of group 2 influenza A virus entry inhibitors | $600K | Chicago Biosolutions, Inc. with UNIVERSITY OF ILLINOIS AT CHICAGO |
| Jul 11, 2017 | NIH | STTR Phase I 4-(Aminomethyl) benzamides as novel anti-Ebola agents | $364K | Chicago Biosolutions, Inc. |
| May 31, 2017 | NIH | STTR Phase I 4-Aminopiperidines as novel anti-influenza agents | $153K | Chicago Biosolutions, Inc. |
| Aug 1, 2016 | NIH | STTR Phase I Aminomethyl benzamides as novel anti Ebola agents | $727K | Chicago Biosolutions, Inc. with UNIVERSITY OF ILLINOIS AT CHICAGO |
| Jul 27, 2016 | NIH | STTR Phase I 4-(Aminomethyl) benzamides as novel anti-Ebola agents | $364K | Chicago Biosolutions, Inc. |
| Jul 11, 2016 | NIH | STTR Phase I GPCR antagonists as anti-Ebola virus entry inhibitors | $298K | MICROBIOTIX, INC. |
| Jun 1, 2016 | NIH | STTR Phase I Aminopiperidines as novel anti influenza agents | $396K | Chicago Biosolutions, Inc. with UNIVERSITY OF ILLINOIS AT CHICAGO |
| May 23, 2016 | NIH | STTR Phase I 4-Aminopiperidines as novel anti-influenza agents | $243K | Chicago Biosolutions, Inc. |
| Mar 1, 2016 | NIH | STTR Phase I Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core | $288K | MICROBIOTIX, INC. |
| Aug 1, 2015 | NIH | STTR Phase I GPCR antagonists as anti-Ebola virus entry inhibitors | $597K | MICROBIOTIX, INC. with UNIVERSITY OF ILLINOIS AT CHICAGO |
| Jun 15, 2015 | NIH | STTR Phase I GPCR antagonists as anti-Ebola virus entry inhibitors | $299K | MICROBIOTIX, INC. |
| Mar 1, 2015 | NIH | STTR Phase I Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core | $577K | MICROBIOTIX, INC. with UNIVERSITY OF ILLINOIS AT CHICAGO |
| Jan 23, 2015 | NIH | STTR Phase I Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core | $289K | MICROBIOTIX, INC. |
| Jan 8, 2015 | NIH | STTR Phase I New small molecule inhibitors of arenaviruses | $298K | MICROBIOTIX, INC. |
| Dec 24, 2014 | NIH | STTR Phase I New heterocyclic inhibitors of filoviruses | $300K | MICROBIOTIX, INC. |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#13
Awards as PI#10
Patents#273
Companies
- Chicago Biosolutions, Inc.Linked by awards · Biotech
- MICROBIOTIX, INC.Linked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.